Year: 2021

Stellantis to Strengthen the Potential of Its European Financing BusinessesCompany intends to create leading operational leasing group and enhanced captive finance arm Strategic and innovative partnerships with leading European banks will enable streamlined customer journey New structure will support the future of mobility servicesAMSTERDAM, December 17, 2021 – Stellantis N.V. (NYSE / MTA / Euronext Paris: STLA) (“Stellantis”) has entered into exclusive negotiations with BNP Paribas Personal Finance (“BNPP PF”), Crédit Agricole Consumer Finance (“CACF”) and Santander Consumer Finance (“SCF”) aimed at better organizing Stellantis’ current European financing landscape to bring consistent and attractive financing activities to all Stellantis brand customers, dealers and distributors. “Following the recent completion of the acquisition...

Review of the remuneration philosophy at Group level Retention plan in performance shares for employees Remuneration of the new Chief Executive Officer Support for the Chief Executive Officer on taking up his position LTI (Long Term Incentive) 2021 plan in performance shares for new executives Governance evolution; change of Chart’s permanent representative on the Board of Directors       La Motte-Fanjas, December 17, 2021 – 07:30 am CET – McPhy (Euronext Paris Compartment C: MCPHY, FR0011742329), (the “Company”), specialized in zero-carbon hydrogen production and distribution equipment (electrolyzers and refueling stations), announces that the Board of Directors, held on December 16 2021, adopted a number of decisions relating to the remuneration policy for employees and its new Chief Executive Officer, the support for the...

PRESS RELEASE                                                Friday, December 17, 2021  2020-2021 Full-year resultsSignificant improvement in margins combined with a sharp reduction in debtSales up 16%, double-digit growth in almost all activities Strong financial performance, with recurring EBITDA up 46% to €78 million for the year and a recurring EBITDA margin of 8.9% Net income of over €43 million Proposed dividend payment of €1.60 per share A consolidated and robust cash position with significantly improved debt ratios including leverage of 0.5x recurring EBITDA2020-21 FULL-YEAR RESULTSEXEL Industries (€ millions)2019‐20202020-2021Change reported  SALES 754.4 876.8 16%  Recurring EBITDA* 53.3 77.8 46%  % of sales 7.1% 8.9%    CURRENT OPERATING INCOME 35.3 54.7 55%  % of sales 4.7% 6.2%    Non‐recurring...

Exclusive rights for a novel early–stage asset acquired from Genoscience Pharma in cholangiocarcinoma in the United States, Canada and Europe Phase 2 clinical program expected to start in 1H 2022 Agreement comes on the heels of today’s other announcement of a long-term global strategic partnership with Ipsen including an exclusive licensing agreement for elafibranor, a Phase 3 asset currently evaluated in Primary Biliary CholangitisLille, France; Cambridge, MA; December 17, 2021 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, is pleased to announce the strengthening of its cholestatic disease franchise through the acquisition of exclusive rights from Genoscience Pharma to develop and commercialize the investigational...

Phase 1 study in patients with advanced solid tumors planned to start in the first quarter of 2022Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, December 17, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the novel kinase inhibitor BAL0891, a potential first-in-class mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division leading to tumor cell death. Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: “We are excited about the FDA approval of the IND for BAL0891, allowing us to proceed with the phase 1 clinical study, which...

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnershipAgreement gives Ipsen global* rights to develop and commercialize GENFIT’s late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVETM, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28mParis (France); December 17, 2021, Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT), have entered into a...

Access to AlenuraTM, a dual mode-of-action advanced clinical candidate for the treatment of acute pain in interstitial cystitis/bladder pain syndrome (IC/BPS) Addressable patient population of at least 6 million1 in the U.S. Liège, Belgium – 17 December 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it has entered into a strategic collaboration with Vaneltix Pharma, Inc. for the development and commercialisation of AlenuraTM as first-line drug treatment for acute pain in interstitial cystitis /bladder pain syndrome (IC/BPS). AlenuraTM is a patented, innovative, clinical-stage bladder instillation product candidate that combines lidocaine, a well-established anaesthetic, in a new alkalinized...

–European Commission Decision Anticipated in Q1 2022- –CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration–   Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland December 17, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of linzagolix, an oral GnRH antagonist for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women of reproductive age. ObsEva’s Marketing Authorisation Application submission was based...